Medicinal chemistry has recently collaborated with a private biotechnology company to optimise a novel small-molecule cardiovascular drug which is currently progressing through clinical trials
The medicinal chemistry company NCE Discovery has recently collaborated on a project with Trigen, a private London-based biotechnology company, to optimise a novel small-molecule cardiovascular drug, which is currently progressing through clinical trials.
Chris Sharman, CEO of NCE Discovery, explained: "A combination of consultancy, synthesis and molecular modelling was used for a number of different programmes Trigen was running.
The company was rapidly expanding during this time and we had to adapt quickly to its changing needs." NCE Discovery is a spin-out company of the Wolfson Institute, University College London.
The company offers a full medicinal chemistry service, from consultation on library selection to design and synthesis of novel molecules through to preliminary structure activity work and first patent filings.
However, unlike many other chemistry outsourcers, NCE also provides a consultancy service to help companies identify the best way to increase the commercial value of their research.
Tony Kennedy, VP of Development at Trigen, said: "NCE Discovery's scientists do not operate like traditional consultants; they integrate themselves into the projects and programmes to the same degree as an internal staff member.
They are very professional and this is important when working on collaborative projects." Chris concluded: "It is a pleasure working with the Trigen team and we are delighted to continue to support the company as it pushes forward its innovative programmes."
